title: Cardiac phosphatase-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase increases glycolysis, hypertrophy, and myocyte resistance to hypoxia.
abstract: During ischemia and heart failure, there is an increase in cardiac glycolysis. To understand if this is beneficial or detrimental to the heart, we chronically elevated glycolysis by cardiac-specific overexpression of phosphatase-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2) in transgenic mice. PFK-2 controls the level of fructose-2,6-bisphosphate (Fru-2,6-P2), an important regulator of phosphofructokinase and glycolysis. Transgenic mice had over a threefold elevation in levels of Fru-2,6-P2. Cardiac metabolites upstream of phosphofructokinase were significantly reduced, as would be expected by the activation of phosphofructokinase. In perfused hearts, the transgene caused a significant increase in glycolysis that was less sensitive to inhibition by palmitate. Conversely, oxidation of palmitate was reduced by close to 50%. The elevation in glycolysis made isolated cardiomyocytes highly resistant to contractile inhibition by hypoxia, but in vivo the transgene had no effect on ischemia-reperfusion injury. Transgenic hearts exhibited pathology: the heart weight-to-body weight ratio was increased 17%, cardiomyocyte length was greater, and cardiac fibrosis was increased. However, the transgene did not change insulin sensitivity. These results show that the elevation in glycolysis provides acute benefits against hypoxia, but the chronic increase in glycolysis or reduction in fatty acid oxidation interferes with normal cardiac metabolism, which may be detrimental to the heart.
authors.affiliation: Department of Physiology, University of Louisville School of Medicine, Louisville, Kentucky, USA.
authors.forename: Qianwen
authors.initials: Q
authors.lastname: Wang
authors.forename: Rajakumar V
authors.initials: RV
authors.lastname: Donthi
authors.forename: Jianxun
authors.initials: J
authors.lastname: Wang
authors.forename: Alex J
authors.initials: AJ
authors.lastname: Lange
authors.forename: Lewis J
authors.initials: LJ
authors.lastname: Watson
authors.forename: Steven P
authors.initials: SP
authors.lastname: Jones
authors.forename: Paul N
authors.initials: PN
authors.lastname: Epstein
mesh_terms: D000818:Animals; D015687:Cell Hypoxia; D004195:Disease Models, Animal; D006019:Glycolysis; D006984:Hypertrophy; D007328:Insulin / Q000378:metabolism; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009119:Muscle Contraction; D009154:Mutation; D009203:Myocardial Infarction / Q000201:enzymology; D015428:Myocardial Reperfusion Injury / Q000201:enzymology* / Q000473:pathology; D009206:Myocardium / Q000201:enzymology* / Q000473:pathology; D032383:Myocytes, Cardiac / Q000201:enzymology; D010084:Oxidation-Reduction; D019308:Palmitic Acid / Q000378:metabolism; D025481:Phosphofructokinase-2 / Q000235:genetics / Q000378:metabolism*; D013997:Time Factors; D015854:Up-Regulation
chemical_list: D007328:Insulin; D019308:Palmitic Acid; D025481:Phosphofructokinase-2